NEFL and myeloid sarcoma: For conversion to clinically diagnosed progressive MS, as shown in Fig. 6B, patients in the 2nd and 3rd tertiles had on average > 4-times higher risk to reach this endpoint compared to those with the lowest serum NfL values at baseline; however, this association failed to reach statistical significance with borderline p values (p = 0.065 and 0.082, respectively).